GlassScriptPhysician profile
Abel Romero-Corral
NPI 1992966360
$2,230.51
in general payments reported to CMS, 2019-2025
18 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $23.94 · 2021: $424 · 2022: $238 · 2023: $337 · 2024: $667 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $457.79 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $450.25 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $321.57 | 2019-2025 | |
| Cardiovascular Systems INC. | $186.91 | 2019-2021 | |
| Abbott Laboratories | $132.04 | 2021 | |
| Heartflow, INC. | $128.04 | 2024 | |
| Medtronic, INC. | $100.16 | 2022-2024 | Corevalve Evolut R, Onyx Frontier |
| Sanofi-Aventis U.S. LLC | $99.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $91.50 | 2019-2025 | Lokelma |
| Novo Nordisk INC | $62.66 | 2024-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $49.12 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $44.74 | 2020-2023 | Eliquis |
| Janssen Pharmaceuticals, INC | $32.79 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.90 | 2019-2024 | Lifevest |
| Pfizer INC. | $16.48 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.85 | 2019 | |
| Elutia, INC. | $10.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abel Romero-Corral listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.